Citations Report

Citation Index - Clinical Investigation [920 Articles]

The articles published in Clinical Investigation have been cited 920 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Clinical Investigation.

  • Henricson E, Abresch R, Han JJ, Nicorici A, Keller EG, de Bie E, McDonald CM.(2013) The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLOS Currents Muscular Dystrophy.

    View at Publisher | View at Google Scholar
  • Kohl CD, Bruns I, Freudigmann M, Scharf G, Schmücker P, et al. (2013) Digitale Archivierung papierbasierter Krankenakten von Studienpatienten-Eckpunktepapier des KKSN, der GMDS und der TMF unter Mitwirkung des BfArM und der Landesüberwachungsbehörde Nordrhein-Westfalen. GMS Medizinische Informatik, Biometrie und Epidemiologie 9: 1-17.

    View at Publisher | View at Google Scholar
  • Freudigmann M, Düsseldorf GS, Mannheim PS, für Arzneimittel GS, Medizinprodukte B (2013)Digitale Archivierung papierbasierter Krankenakten von Studienpatienten–Eckpunktepapier des KKSN, der GMDS und der TMF unter Mitwirkung des BfArM und der Landesüberwachungsbehörde Nordrhein-Westfalen Digital archiving of paper-based patient records of clinical trial subjects–a key issues paper of KKSN, GMDS, and TMF in collaboration with the Federal Institute for Drugs and Medical Devices (BfArM) and the Health Authority Northrhine-Westphalia 9:3.

    View at Publisher | View at Google Scholar
  • McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR, Hoffman EP, Cnaan A. The cooperative international neuromuscular research group Duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle & nerve. 2013 Jul 1;48(1):32-54.

    View at Publisher | View at Google Scholar
  • Rech J (2015) Organisation einer Studienambulanz und prüfstellenspezifische Formalitäten. InStudy Nurse/Studienassistenz: 9-15.

    View at Publisher | View at Google Scholar
  • Bhat J, Oberg HH, Kabelitz D (2015) Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors. Cellular immunology 296:50-6.

    View at Publisher | View at Google Scholar
  • Henricson E, Abresch R, Han JJ, Nicorici A, Keller EG, Elfring G, Reha A, Barth J, McDonald CM.(2012) Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences. PLOS Currents Muscular Dystrophy.

    View at Publisher | View at Google Scholar
  • Qiu X, Xiao X, Li N, Li Y (2017) Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases. Progress in Neuro-Psychopharmacology and Biological Psychiatry 72: 60-72.

    View at Publisher | View at Google Scholar
  • Mercuri E, Muntoni F.(2013) Muscular dystrophy: new challenges and review of the current clinical trials. Current opinion in pediatrics ;25:701-707.

    View at Publisher | View at Google Scholar
  • Silva MF (2014) Relação entre a irregularidade do tratamento poliquimioterápico e a ocorrência de episódios reacionais em pacientes com Hanseníase. Diss.

    View at Publisher | View at Google Scholar
  • Mazzone ES, Vasco G, Palermo C, Bianco F, Galluccio C, Ricotti V, Castronovo AD, Mauro MS, Pane M, Mayhew A, Mercuri E.(2012) A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Developmental Medicine & Child Neurology ;54:879-885.

    View at Publisher | View at Google Scholar
  • Saxena AK, Azad CS (2016) Neglected Tropical Bacterial Diseases 1-76.

    View at Publisher | View at Google Scholar
  • Govoni A, Magri F, Brajkovic S, Zanetta C, Faravelli I, Corti S, Bresolin N, Comi GP.(2013) Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cellular and molecular life sciences ;70:4585-4602.

    View at Publisher | View at Google Scholar
  • Poole RM (2014 ) Belinostat: first global approval. Drugs 4: 1543-1554.

    View at Publisher | View at Google Scholar
  • Goemans N, Van den Hauwe M, Wilson R, Van Impe A, Klingels K, Buyse G(2013) Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscular Disorders ;23:618-623.

    View at Publisher | View at Google Scholar
  • Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S, D’Amico A, Messina S, Battini R, Scutifero M, Petillo R.(2014) Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscular Disorders ;24:201-206.

    View at Publisher | View at Google Scholar
  • De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, et al. (2015 ) Optimization of a Novel Binding Motif to (E)-3-(3, 5-Difluoro-4-((1 R, 3 R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2, 3, 4, 9-tetrahydro-1 H-pyrido [3, 4-b] indol-1-yl) phenyl) acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. Journal of Medicinal Chemistry 58: 8128-8140.

    View at Publisher | View at Google Scholar
  • Takeuchi F, Yonemoto N, Nakamura H, Shimizu R, Komaki H, Mori-Yoshimura M, Hayashi YK.,et.al.(2013) Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of neurology ;260:3023-3029.

    View at Publisher | View at Google Scholar
  • Callis R, Rabow A, Tonge M, Bradbury R, Challinor M, et al. (2015) A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs). Journal of biomolecular screening 20: 748-759.

    View at Publisher | View at Google Scholar
  • Pane M, Scalise R, Berardinelli A, D’Angelo G, Ricotti V, Alfieri P, Moroni I, Hartley L, Pera MC.,et.al.(2013). Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscular Disorders ;23:451-455.

    View at Publisher | View at Google Scholar
  • Ellis JA, Vroom E, Muntoni F. (2013) 195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands. Neuromuscul Disord ;23:682-289. View at Publisher | View at Google Scholar
  • Hafkin B, Kaplan N, Hunt TL (2015) Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects. Future Microbiology 10: 1805-1813.

    View at Publisher | View at Google Scholar
  • Han JJ, Kurillo G, Abresch RT, De Bie E, Nicorici A, Bajcsy R. (2015) Upper extremity 3‐dimensional reachable workspace analysis in dystrophinopathy using Kinect. Muscle & nerve ;52:344-355.

    View at Publisher | View at Google Scholar
  • Hafkin B, Kaplan N, Murphy B (2015 ) Efficacy and safety of AFN-1252, the first staphylococcus-specific antibacterial agent, in the treatment of ABSSSI, including patients with significant co-morbidities. Antimicrobial agents and chemotherapy AAC-01741.

    View at Publisher | View at Google Scholar
  • Nève V, Cuisset JM, Edmé JL, Carpentier A, Howsam M, Leclerc O, Matran R. (2013)Sniff nasal inspiratory pressure in the longitudinal assessment of young Duchenne muscular dystrophy children. European Respiratory Journal ;42:671-680.

    View at Publisher | View at Google Scholar
  • Bodewes FA, Verkade HJ, Taminiau JA, Borowitz D, Wilschanski M (2015) Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation. Journal of Cystic Fibrosis 14: 169-177.

    View at Publisher | View at Google Scholar
  • Konstan MW, Accurso FJ, Nasr SZ, Ahrens RC, Graff GR (2013) Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis. Clinical investigation 3:723.

    View at Publisher | View at Google Scholar
  • Mercuri E, McDonald C, Mayhew A, Florence J, Mazzone E, Bianco F, Decostre V, Servais L, Ricotti V, Goemans N, Vroom E. (2012) International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy: Rome, 15–16 February 2012. Neuromuscular Disorders ;22:1025-1028.

    View at Publisher | View at Google Scholar
  • Heubi JE, Schaeffer D, Ahrens RC, Sollo N, Strausbaugh S, et al. (2016 ) Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. The Journal of pediatrics 176: 156-161.

    View at Publisher | View at Google Scholar
  • Whitcomb DC, Bodhani A, Beckmann K, Sander-Struckmeier S, Liu S, et al. (2016 ) Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus. Pancreas 45: 679-686.

    View at Publisher | View at Google Scholar
  • Han JJ, Kurillo G, Abresch RT, Nicorici A, Bajcsy R.(2011) Validity, reliability, and sensitivity of a 3D vision sensor-based upper extremity reachable workspace evaluation in neuromuscular diseases. PLoS currents;5.

    View at Publisher | View at Google Scholar
  • Vry J, Schubert IJ, Semler O, Haug V, Schönau E, Kirschner J. (2014) Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy. european journal of paediatric neurology 18:140-149.

    View at Publisher | View at Google Scholar
  • Han JJ, Kurillo G, Abresch RT, Bie E, Nicorici A, Bajcsy R. (2015) Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect. Muscle & nerve ;51:168-175.

    View at Publisher | View at Google Scholar
  • Rutkove SB, Darras BT. (2016) Electrical impedance myography for the assessment of children with muscular dystrophy: a preliminary study. InJournal of Physics: Conference Series IOP Publishing : 434;1,

    View at Publisher | View at Google Scholar
  • Woo SM, Joo J, Kim SY, Park SJ, Han SS, et al. (2016) Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology 16: 1099-1105.

    View at Publisher | View at Google Scholar
  • Dack K, Peres A, Thrift L, Talbot S, Madge S (2015) Understanding and managing cystic fibrosis: The growing number of people living longer with the disease means that care is increasingly shifting to community teams. Kamilla Dack and colleagues describe the main features of cystic fibrosis, and its treatment and management. Primary Health Care 25: 18-24.

    View at Publisher | View at Google Scholar
  • Gloss D, Moxley RT, Ashwal S, Oskoui M. (2016) Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology ;86:465-472.

    View at Publisher | View at Google Scholar
  • Herron CE, Mason AE (2016) Investigating the Use of Chloroquine as Antineoplastic Therapy.

    View at Publisher | View at Google Scholar
  • Shklyar I, Geisbush TR, Mijialovic AS, Pasternak A, Darras BT, Wu JS, Rutkove SB, Zaidman CM.(2015) Quantitative muscle ultrasound in Duchenne muscular dystrophy: a comparison of techniques. Muscle & nerve ;51:207-213.

    View at Publisher | View at Google Scholar
  • Espina V (2013) T~ Lfi (Doctoral dissertation, George Mason University).

    View at Publisher | View at Google Scholar
  • McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A. Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases.

    View at Publisher | View at Google Scholar
  • Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, Daniels MJ.,et.al.. (2016) Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Annals of neurology.

    View at Publisher | View at Google Scholar
  • Bodor M, Mcdonald CM. (2013)Why short stature is beneficial in Duchenne muscular dystrophy. Muscle & nerve ;48:336-342.

    View at Publisher | View at Google Scholar
  • Pane M, Fanelli L, Mazzone ES, Olivieri G, D'Amico A, Messina S, Scutifero M, Battini R.,et.al..(2015) Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscular Disorders ;25:749-753.

    View at Publisher | View at Google Scholar
  • De Sanctis R, Pane M, Sivo S, Ricotti V, Baranello G, Frosini S, Mazzone E, Bianco F, Fanelli L, Main M, Corlatti A(2015) Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscular Disorders ;25:14-8.

    View at Publisher | View at Google Scholar
  • Strehle EM, Straub V(2015) . Recent advances in the management of Duchenne muscular dystrophy. Archives of disease in childhood :archdischild-2014.

    View at Publisher | View at Google Scholar
  • Johnson LB, Florence JM, Abresch RT.(2012) Physical therapy evaluation and management in neuromuscular diseases. Physical medicine and rehabilitation clinics of North America ;23:633-651.

    View at Publisher | View at Google Scholar
  • Townsend EL, Tamhane H, Gross KD. (2015) Effects of AFO Use on Walking in Boys With Duchenne Muscular Dystrophy: A Pilot Study: A Pilot Study. Pediatric Physical Therapy ;27:24-29.

    View at Publisher | View at Google Scholar
  • Burch PM, Pogoryelova O, Goldstein R, Bennett D, Guglieri M, Straub V, Bushby K, Lochmüller H, Morris C.(2015) Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy. Journal of neuromuscular diseases ;2:241-255.

    View at Publisher | View at Google Scholar
  • Malheiros SR, da Silva TD, Favero FM, de Abreu LC, Fregni F, Ribeiro DC, de Mello Monteiro CB. (2016)Computer task performance by subjects with Duchenne muscular dystrophy. Neuropsychiatric disease and treatment ;12:41.

    View at Publisher | View at Google Scholar

Relevant Topics